張俊彥 Jang-Yang Chang

Jang-Yang,Chang|

Jang-Yang Chang,M.D.

E-mail：z10208083@email.ncku.edu.tw

TEL：06-2353535 ext 5000(off.) ext 65122/65129(lab.)

FAX：06-2353660

　

Educations / Professional Experience

　

Educations

1982                M.D. National Defense Medical Center, Taipei, Taiwan, R.O.C.
　 　 　
　 Current Position Dean, National Cheng Kung University College of Medicine, Tainan, Taiwan
　 　 Distinguished Investigator &Director, National Institute of Cancer Research, NHRI, Taiwan
　 　 　
　 Professional Experience 2013~ Dean, National Cheng Kung University College of Medicine, Tainan, Taiwan
　 　 2008/09 Distinguished Investigator &Director, National Institute of Cancer Research, NHRI, Taiwan
　 　 2008/01 Director, National Institute of Cancer Research, NHRI, Taiwan
　 　 2007/08 Joined Professor, Medical School, NUKU, Taiwan
　 　 2007/08 Attending Physician, Division of hematology/Oncology, NCKUH, Taiwan
　 　 2006/01~ Deputy Director, National Institute of Cancer Research, NHRI, Taiwan
　 　 2004/6-2008 Chairman, Safety and Data Monitoring committee, TCOG, Taiwan
　 　 2004/04 Investigator, Division of Cancer Research, NHRI, Taiwan
　 　 2003-2005 常務理事, Chinese Oncology Society, Taiwan
　 　 2003/08 Adjunct Professor, Internal Medicine, NDMC, Taiwan
　 　 2001 Board member, Chinese Oncology Society, Taiwan
　 　 2000/9-2004/3 Associate investigator, Division of Cancer Research, NHRI, Taiwan
　 　 1999 Board member, Sino-American Cancer Foundation, Taiwan
　 　 1997 Senior Attending physician, Division of Cancer Research, NHRI, Taiwan
　 　 1997 Chief, Hematology / Oncology, Cheng-Hsien Medical Center, Taiwan
　 　 1997-2006 Adjunct Attending physician, Department of Oncology, NTUH, Taiwan
　 　 1997-2001 General Secretary, Chinese Oncology Society, Taiwan
　 　 1994-2003/7 Associate Professor, Internal Medicine, NDMC, Taiwan
　 　 1994-1996 Board member, Chinese BMT Society, Taiwan
　 　 1993 Chief, Medical Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan
　 　 1991-1992 Attending physician, Medical Mission in Republic of Central Africa
　 　 1989-1991 Visiting Scholar, Department of Pharmacology, Yale Medical School
　 　 1987 Attending Physician, Hematology / Oncology, Tri-Service General Hospital, NDMC, Taiwan
　 　 1987-1989 Fellow of Medical Oncology Training Program, Institute of Biomedical Science, Academia Sinica, Taiwan
　 　 1986-1987 Chief Resident, Division of Hematology / Oncology, Department of Internal Medicine, TSGH, NDMC, Taiwan
　 　 1982-1986 Resident, Department of Medicine, TSGH, NDMC, Taiwan
　 　 1981-1982 Internship training, Tri-Service General Hospital

　

Expertise /Research Interests

　

Medical Oncology, Cancer pharmacology and drug discovery

　

Dr. Chang's research interests focus on three fields; (1) study the mechanisms of drug resistance, especially camptothecins, and the relationship between CPT-resistance and DNA repair; (2) anti-cancer drug development, focusing on topoisomerase I and II and tubulin inhibitors; (3) regulation of DNA repair enzyme, MGMT.

　

 　
　 Major Research Interests
　

  1. Development of anticancer drugs

  2. Study the mechanisms of anticancer drug resistance.
　 　
　 Research projects：
　
Clinical studies：

  1. A phase III study of postoperative adjuvant chemoradiotherapy for patients with stage III and IVb stomach cancer. (PI)

  2. A phase II study of gemcitabine and vinorelbine in cisplatin-resistant nasopharyngeal carcinoma patients. (co-PI)

  3. A phase I study of PI-88 in advanced malignancies. (co-PI)

  4. A phase I and PK study of thalidomide in hepatocellular carcinoma. (co-PI)

  5. A phase II study of weekly CPT-11 in recurrent NPC. (PI)

  6. A phase II study of weekly oxaliplatin plus HDFL in patients with advanced gastric cancer (co-PI)

  7. A phse II study of taxol, UFT and leucovorin in patients with advanced gastric cancer. (co-PI)

  8. A phase I/II study of docetaxel, cisplatin and HDFL in patients with advanced gastric cancer. (PI)

  9. A phase III study of thalidomide in patients with poor liver function hepatocellular carcinoma. (co-PI)

  10. Phase I and PK studies of PEP02 in patients with advanced malignancies. (PI)

  11. Phase I study of PEP02 with HDFL in patients with advanced malignancies. (co-PI)

  12. Phase I and PK study of biweekly PEP02 in patients with advanced colorectal cancer (PI).
　
Basic studies：

  1. Study the distribution of somatostatin receptor in human cancer tissue.

  2. Study the mechanism of CPT resistance in human nasopharyngeal cancer cells.

  3. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.

  4. Synthesis and structure-activity relationships of new AHMA derivatives as topoisomerase-II mediated antitumor agents.

  5. Study the indole derivatives as antitumor agents.

  6. Study the mechanims of action of BPR0Y007, a novel anticancer agent.

  7. Study the role of O6-MGMT in determining the cytotoxicty of topoisomerase I inhibitors.

  8. Transcriptional inhibition of O6MGMT gene of topoisomerase I inhibitors.

  9. Isolation the putative transporter responsible for resistance to topoisomerase I inhibitors in a vincristine-resistant cell line.

  10. Study the mechanism of action of a potential antitumor agent isolated from a herb medicine.

  11. Study the interaction of arsenic trioxide with antitumor agents.

  12. Study the interaction of new topoisomerase I inhibitor, DB67, with other antitumor agents.

  13. Study the pathway of BPR0Y007-induced apoptosis.

  14. Study on the regulation of DNA repair enzyme, MGMT, in human cancer cells.

  15. Study on the development of anti-tubulin compounds
　

 Award
　
　 2010 Outstanding Poster Award, The 15th Annual Taiwan Joint Cancer Conference, 2010
　 2008 Outstanding Poster Award, The 13rd Annual Taiwan Joint Cancer Conference
　 2007 Outstanding Poster Award, The 12nd Annual Taiwan Joint Cancer Conference
　 2006 Outstanding Poster Award, The 11th Annual Taiwan Joint Cancer Conference
　 2005 徐千田防癌研究基金癌症傑出研究獎 (基礎組)
　 2005 Outstanding Poster Award, The 10th Annual Taiwan Joint Cancer Conference
　 2004 Outstanding Poster award, The 9th Annual Taiwan Joint Cancer Conference
　 2003 Outstanding Poster award, The 8th Annual Taiwan Joint Cancer Conference
　 2001 Outstanding Poster award, The 6th Annual Taiwan Joint Cancer Conference